These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

598 related items for PubMed ID: 19493471

  • 21. Effects of nadroparin, enoxaparin, and unfractionated heparin on endogenous formation of factor Xa and IIa and on thrombelastometry profiles in cord versus adult blood.
    Cvirn G, Hoerl G, Tafeit E, Heinl N, Wodrig K, Wagner T, Koestenberger M, Juergens G.
    Neonatology; 2011; 100(1):23-31. PubMed ID: 21150227
    [Abstract] [Full Text] [Related]

  • 22. Anticoagulation monitoring part 2: Unfractionated heparin and low-molecular-weight heparin.
    Spinler SA, Wittkowsky AK, Nutescu EA, Smythe MA.
    Ann Pharmacother; 2005; 39(7-8):1275-85. PubMed ID: 15956240
    [Abstract] [Full Text] [Related]

  • 23. Prothrombinase-induced clotting time assay for determination of the anticoagulant effects of unfractionated and low-molecular-weight heparins, fondaparinux, and thrombin inhibitors.
    Calatzis A, Peetz D, Haas S, Spannagl M, Rudin K, Wilmer M.
    Am J Clin Pathol; 2008 Sep; 130(3):446-54. PubMed ID: 18701419
    [Abstract] [Full Text] [Related]

  • 24. Anticoagulant mechanisms of covalent antithrombin-heparin investigated by thrombelastography. Comparison with unfractionated heparin and low-molecular-weight heparin.
    Atkinson HM, Mewhort-Buist TA, Berry LR, Chan AK.
    Thromb Haemost; 2009 Jul; 102(1):62-8. PubMed ID: 19572069
    [Abstract] [Full Text] [Related]

  • 25. Determination of enoxaparin with rotational thrombelastometry using the prothrombinase-induced clotting time reagent.
    Schaden E, Schober A, Hacker S, Spiss C, Chiari A, Kozek-Langenecker S.
    Blood Coagul Fibrinolysis; 2010 Apr; 21(3):256-61. PubMed ID: 20087172
    [Abstract] [Full Text] [Related]

  • 26. Biomarkers and coagulation tests for assessing the biosimilarity of a generic low-molecular-weight heparin: results of a study in healthy subjects with enoxaparin.
    Kuczka K, Harder S, Picard-Willems B, Warnke A, Donath F, Bianchini P, Parma B, Blume H.
    J Clin Pharmacol; 2008 Oct; 48(10):1189-96. PubMed ID: 18716314
    [Abstract] [Full Text] [Related]

  • 27. Xa inhibition and coagulation activity--the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals.
    Oldgren J, Johnston N, Siegbahn A.
    Am Heart J; 2008 Mar; 155(3):493.e1-8. PubMed ID: 18294482
    [Abstract] [Full Text] [Related]

  • 28. Generic low-molecular-weight heparins: some practical considerations.
    Fareed J, Leong WL, Hoppensteadt DA, Jeske WP, Walenga J, Wahi R, Bick RL.
    Semin Thromb Hemost; 2004 Dec; 30(6):703-13. PubMed ID: 15630677
    [Abstract] [Full Text] [Related]

  • 29. The correlation between plasma anti-factor Xa activity and haemostatic tests in healthy dogs, following the administration of a low molecular weight heparin.
    Mischke R, Grebe S.
    Res Vet Sci; 2000 Dec; 69(3):241-7. PubMed ID: 11124095
    [Abstract] [Full Text] [Related]

  • 30. The activity of unfractionated heparin and low molecular weight heparins in rabbit plasma--the need for using absolute anti-factor Xa and antithrombin activities.
    Peyrou V, Béguin S, Boneu B, Hemker HC.
    Thromb Haemost; 1997 Feb; 77(2):312-6. PubMed ID: 9157588
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Bioequivalence of generic and branded subcutaneous enoxaparin: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy Chinese male subjects.
    Feng L, Shen-Tu J, Liu J, Chen J, Wu L, Huang M.
    Clin Ther; 2009 Jul; 31(7):1559-67. PubMed ID: 19695405
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Evaluation of coagulation and anti-Xa factor when using a heparin-coated AN69ST® dialyser.
    Sánchez-Canel JJ, Pons-Prades R, Salvetti ML, Seores A, Vázquez M, Pérez-Alba A, Tamarit E, Calvo-Gordo C, Villatoro J.
    Nefrologia; 2012 Jul; 32(5):605-12. PubMed ID: 23013946
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 30.